SCHEMBL3775967

SCHEMBL3775967

CC(C)(C)OC(=O)N1CCC(Nc2nc(N3CCOCC3)c3cc(Cl)ccc3n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.49
MTOR P42345 5/20 0.49
PIK3CG P48736 4/20 0.49
ATR Q13535 2/20 0.49
AURKB Q96GD4 1/20 0.49
CNR1 P21554 3/20 0.49
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
IDH1 O75874 1/20 0.43
IDH2 P48735 1/20 0.43
TLR9 Q9NR96 2/20 0.43
DNMT3A Q9Y6K1 1/20 0.43
PIK3R1 P27986 1/20 0.43
ADORA2A P29274 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3772303 0.85 NSD2 (0.59) PIK3CAMTORPIK3CGATRAURKB
SCHEMBL13015077 0.79 PDE10A (0.46) PIK3CAMTORALDH1A1NPC1MAPT
SCHEMBL3775591 0.78 CNR1 (0.48) CNR1ALDH1A1NPC1MAPTMAPK1
Hydrochloric Acid SCHEMBL3775275 0.78 PDE10A (0.46) PIK3CAMTORALDH1A1NPC1MAPT
SCHEMBL12225466 0.76 GBA1 (0.59) PIK3CAMTORIDH1IDH2TLR9
SCHEMBL3777218 0.76 NSD2 (0.60) ALDH1A1TLR9DNMT3ANSD2
SCHEMBL2532827 0.75 TLR9 (0.48) CNR1HTTNPSR1IDH1TLR9
SCHEMBL2532832 0.75 TLR9 (0.48) CNR1HTTNPSR1IDH1TLR9
SCHEMBL23360676 0.74 CNR1 (0.61) PIK3CACNR1ALDH1A1NPC1MAPT
SCHEMBL29863184 0.74 CNR1 (0.61) PIK3CACNR1ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855194-B2 Pyrimidine, quinazoline, pteridine and triazine derivatives HOFFMANN-LA ROCHE INC. (US) 2010-12-21 US disclosed
EP-2001867-B1 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2009-07-01 EP disclosed
EP-2001867-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
WO-2007110340-A2 PYRIMIDINE, QUINAZOLINE, PTERIDINE AND TRIAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225271-A1 Pyrimidine, quinazoline, pteridine and triazine derivatives SSTR5, SSTR3, SSTR1 PIK3CA 747/4885MTOR 1360/4885PIK3CG 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.